ClinicalTrialsFinder
RecruitingNCT06308510

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

Sponsor

Erasmus Medical Center

Enrollment

63 participants

Start Date

Dec 17, 2024

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer

Summary

Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Gastric cancer patients:
  • Age ≥18 years old;
  • Written informed consent according to the ICH-GCP and national/local regula-tions.
  • Operable patients who will undergo a planned diagnostic laparoscopy for a benign indication bariatric or gallbladder disease);
  • Age ≥18 years old;
  • Written informed consent according to the ICH-GCP and national/local regulations.

Exclusion Criteria4

  • \- Language difficulty, dementia or altered mental status prohibiting the under-standing and giving of informed consent.
  • non-cancer controls:
  • Active inflammation or infection;
  • Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry (exceptions include but are not limited to, non-melanoma skin cancers; in situ bladder cancer, or in situ co-lon cancers; in situ cervical cancers/dysplasia; or breast carcinoma in situ).

Interventions

OTHERcollection additional peritoneal lavage fluid

collection additional peritoneal lavage fluid

Locations(1)

Erasmus MC

Rotterdam, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06308510

Related Trials

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT051871821 location

Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma

NCT072774391 location

Study for AZD4360 in Participants With Advanced Solid Tumours

NCT0692192817 locations

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria

NCT074811102 locations

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT0570222944 locations